Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H26O2 |
Molecular Weight | 286.4085 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=RSIHSRDYCUFFLA-DYKIIFRCSA-N
InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,11,14-17,21H,3-6,8,10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1
Molecular Formula | C19H26O2 |
Molecular Weight | 286.4085 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/vet/equipoise.html
Sources: https://www.drugs.com/vet/equipoise.html
Boldenone (INN, BAN), also known as Δ1-testosterone, 1-dihydrotestosterone, or androsta-1,4-dien-3-one-17β-ol (train name Equipoise) is a long-acting injectable anabolic agent for horses, supplied in a vial providing 50 mg boldenone undecylenate per mL in sesame oil with 3% (w/v) benzyl alcohol as a preservative. The activity of boldenone is mainly anabolic, with a low androgenic potency. Boldenone will increase nitrogen retention, protein synthesis increases appetite and stimulates the release of erythropoietin in the kidneys. Boldenone was synthesized in an attempt to create a long-acting injectable methandrostenolone (Dianabol), for androgen deficiency disorders. Boldenone acts similar to methandrostenolone with fewer adverse androgenic effects. Although commonly compared to nandrolone, boldenone lacks progesterone receptor interaction and all the associated progestogenic side effects. Equipoise (Boldenone Undecylenate Injection) is recommended as an aid for treating debilitated horses when an improvement in weight, haircoat or general physical condition is desired. Debilitation often follows disease or may occur following overwork and overexertion. Boldenone improves the general state of debilitated horses, thus aiding in correcting weight losses and improving appetite. It is not a substitute for a well-balanced diet. Optimal results can be expected only when good management and feeding practices are utilized. Boldenone should be considered only as adjunctive therapy to other specific and supportive therapy for diseases, surgical cases, and traumatic injuries.
CNS Activity
Originator
Sources: https://www.google.com/patents/US2962422
Curator's Comment: # Pfizer & Co C
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11252818 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Equipoise Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Microbial transformation of (+)-androsta-1 ,4-diene-3,17-dione by Cephalosporium aphidicola. | 2002 Dec |
|
Transformations of testosterone and related steroids in Absidia glauca culture. | 2003 |
|
A new bacterial steroid degradation gene cluster in Comamonas testosteroni TA441 which consists of aromatic-compound degradation genes for seco-steroids and 3-ketosteroid dehydrogenase genes. | 2003 Aug |
|
Transformations of testosterone and related steroids by Botrytis cinerea. | 2003 Jan |
|
Confirmatory analysis of 17beta-boldenone, 17alpha-boldenone and androsta-1,4-diene-3,17-dione in bovine urine by liquid chromatography-tandem mass spectrometry. | 2003 Jun 15 |
|
Interactions of androgens, green tea catechins and the antiandrogen flutamide with the external glucose-binding site of the human erythrocyte glucose transporter GLUT1. | 2003 Oct |
|
Method development for corticosteroids and anabolic steroids by micellar liquid chromatography. | 2003 Sep 5 |
|
Evidence for false-positive results for boldenone testing of veal urine due to faecal cross-contamination during sampling. | 2004 Aug |
|
Biotransformation of (+)-androst-4-ene-3,17-dione. | 2004 Dec |
|
Direct detection of boldenone sulfate and glucuronide conjugates in horse urine by ion trap liquid chromatography-mass spectrometry. | 2004 Dec 25 |
|
Paracoccidioidomycosis in a woman with idiopathic hirsutism. | 2004 Jul |
|
Presence and metabolism of the anabolic steroid boldenone in various animal species: a review. | 2004 Jun |
|
Complete 1H and 13C NMR spectral assignment of 17-hydroxy epimeric sterols with planar A or A and B rings. | 2004 Mar |
|
Confirmatory analysis of 17beta-boldenone, 17alpha-boldenone and androsta-1,4-diene-3,17-dione in bovine urine, faeces, feed and skin swab samples by liquid chromatography-electrospray ionisation tandem mass spectrometry. | 2004 Mar 5 |
|
Production of androgens by microbial transformation of progesterone in vitro: a model for androgen production in rivers. | 2004 Nov |
|
Fetal alcohol exposure alters neurosteroid levels in the developing rat brain. | 2004 Sep |
|
Detection of endogenous boldenone in the entire male horses. | 2004 Sep 5 |
|
The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. | 2005 |
|
ADD, AED, alpha-boldenone and epitestosterone neo formation in calf faeces: preliminary results. | 2005 Aug |
|
Steroids' transformations in Penicillium notatum culture. | 2005 Mar |
|
Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. | 2005 May |
|
A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. | 2005 May |
|
Androstadienetrione, a boldenone-like component, detected in cattle faeces with GC-MS(n) and LC-MS(n). | 2005 Sep |
|
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals. | 2005 Sep 8 |
|
Rapid test by liquid chromatography/tandem mass spectrometry to evaluate equine urine reactivity towards 17beta-OH steroids. | 2006 |
|
Characterization of boldione and its metabolites in human urine by liquid chromatography/electrospray ionization mass spectrometry and gas chromatography/mass spectrometry. | 2006 |
|
Multi residue screening of intact testosterone esters and boldenone undecylenate in bovine hair using liquid chromatography electrospray tandem mass spectrometry. | 2006 Jan 2 |
|
Analysis of anabolic steroids in hair by GC/MS/MS. | 2007 Apr |
|
Phytosterol consumption and the anabolic steroid boldenone in humans: a hypothesis piloted. | 2007 Jul |
|
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. | 2007 Jun 1 |
|
An in vitro study on metabolism of 17beta-boldenone and boldione using cattle liver and kidney subcellular fractions. | 2007 Mar 14 |
|
Excretion profile of boldenone in urine of veal calves fed two different milk replacers. | 2007 Mar 14 |
|
Formation of boldenone and boldenone-analogues by maggots of Lucilia sericata. | 2007 Mar 14 |
|
Development and validation of a liquid chromatography-tandem mass spectrometry method for the separation of conjugated and unconjugated 17alpha- and 17beta-boldenone in urine sample. | 2007 Mar 14 |
|
Development of a method which discriminates between endogenous and exogenous beta-boldenone. | 2007 Mar 14 |
|
Pathology of the testicle and sex accessory glands following the administration of boldenone and boldione as growth promoters in veal calves. | 2007 Nov |
|
A new highly specific and robust yeast androgen bioassay for the detection of agonists and antagonists. | 2007 Nov |
|
Determination of anabolic steroids in muscle tissue by liquid chromatography-tandem mass spectrometry. | 2007 Oct 17 |
|
Boldenone, boldione, and milk replacers in the diet of veal calves: the effects of phytosterol content on the urinary excretion of boldenone metabolites. | 2007 Oct 3 |
|
Integrated analytical approach in veal calves administered the anabolic androgenic steroids boldenone and boldione: urine and plasma kinetic profile and changes in plasma protein expression. | 2007 Sep |
|
Fractionation of free and conjugated steroids for the detection of boldenone metabolites in calf urine with ultra-performance liquid chromatography/tandem mass spectrometry. | 2008 Aug |
|
Nonlinear immunofluorescent assay for androgenic hormones based on resonant structures. | 2008 Aug 18 |
|
Nutritional supplements cross-contaminated and faked with doping substances. | 2008 Jul |
|
Cytogenetic and clinical studies of a male infant with disorder of sexual development: case report. | 2008 Nov |
|
The development of multiple drug use among anabolic-androgenic steroid users: six subjective case reports. | 2008 Nov 28 |
|
Quantification of 19-nortestosterone sulphate and boldenone sulphate in urine from male horses using liquid chromatography/tandem mass spectrometry. | 2008 Oct |
|
Simultaneous doping analysis of main urinary metabolites of anabolic steroids in horse by ion-trap gas chromatography-tandem mass spectrometry. | 2008 Sep |
|
Simultaneous measurement of boldenone (alpha and beta), ADD, testosterone, epitestosterone and AED in bovine faeces. | 2008 Sep |
|
The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism. | 2009 Mar |
|
Analysis of anabolic steroids in hair: time courses in guinea pigs. | 2009 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/vet/equipoise.html
The dosage for horses is 0.5 mg per pound of body weight intramuscularly. Treatment may be repeated at three week intervals.
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11252818
The rhAR preparation was diluted 150 in assay buffer (5 mM Na2HP04, 150 mM NaCl, pH 7.2, containing 0.16% w/v protease inhibitor mix and 0.1% bovine serum albumin). Aliquots of 0.5 mL were incubated at 04°C for 16 hours with a constant amount of 0.4 nM 3H-DHT and in the presence or absence of increasing concentrations of Boldenone . DHT was used in all experiments as standard. To separate bound and free ligand, the receptor preparation was incubated with 100 mkL of dextrancoated charcoal (4%) charcoal and 0.4% dextran in assay buffer) for 5 min before centrifugation at 2000 x g for 15 min at 4°C. 0.4 mL of the supernatant was transferred into scintillation vials, mixed with 3 mL Xylofluor and counted. Specific binding represents the relative difference of total binding and non specific binding observed in the presence of a 250 fold surplus of unlabelled DHT.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:21:19 GMT 2023
by
admin
on
Fri Dec 15 15:21:19 GMT 2023
|
Record UNII |
5H7I2IP58X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 522.204
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
||
|
WIKIPEDIA |
Designer-drugs-Boldenone
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
||
|
NCI_THESAURUS |
C2360
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
||
|
DEA NO. |
4000
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
79102
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
5H7I2IP58X
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
BOLDENONE
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
846-48-0
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
13308
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106059
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
DB01541
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
2464
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
SUB05869MIG
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
m2597
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID20894201
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
34584
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
212-686-0
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
C013915
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
100000086347
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
C75064
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY | |||
|
2289408
Created by
admin on Fri Dec 15 15:21:19 GMT 2023 , Edited by admin on Fri Dec 15 15:21:19 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |